COVID-19 — United Kingdom
Abstract
——–
Importance
Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19.
Objective
To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Design, setting, and participants
The BLAZE-1 study is a randomized phase 2/3 trial at 49 US
…
